AMP presented testimony to the Patent and Trademark Office requesting moratorium on human gene patenting

February 16, 2012

Today, the Association for Molecular Pathology (AMP) asked the U.S. Patent and Trademark Office (USPTO) to place a moratorium on the issuing of patents on human genes during testimony presented at an Agency hearing on genetic diagnostic testing. AMP is the lead plaintiff of 20 plaintiffs in an American Civil Liberties Union (ACLU) sponsored lawsuit challenging the validity of patents on two hereditary breast and ovarian cancer genes, BRCA1 and BRCA2. AMP joined the litigation because of its members' first hand view of the harmful effects of gene patents on patients with genetic diseases and their at-risk family members. "Every day, AMP members witness the ability of genetic testing to better patients' lives and improve their health. Unfortunately, they also experience firsthand the challenges imposed by gene patents that interfere with the practice of medicine and limit their treatment decisions," said Mary Williams, Executive Director of AMP.

AMP believes previous scientific and federal advisory committee publications, and the common knowledge of practitioners in the field, provide ample evidence for the patient harms and negative impact on testing associated with gene patents, and argue against and genotype-phenotype associations as patentable subject matter. Further, AMP is also concerned that because the USPTO is not a healthcare focused agency it does not possess the needed expertise and resources to adequately assess the impact of patents on patients' ability to obtain confirmatory testing. For these reasons, AMP strongly urges the USPTO to base its assessment of the impact of gene patents on genetic testing on the report published by the Department of Health and Human Services (HHS) Secretary's Advisory Committee on Genetics, Health, and Society (SACGHS) published in April 2010 entitled, "Gene Patents and Licensing Practices and Their Impact on Patient Access to Genetic Tests."

Ms. Williams explained, "This almost 400 page report represents approximately four years of active investigation and study and is an important reference on the subject. AMP encourages the USTPO to adopt the recommendations contained in the report."

"Patients are increasingly being harmed by patents that claim ownership over the biological relationships between genetic variants and clinical disease," stated Roger D. Klein, MD JD, Chair of AMP's Professional Relations Committee. For example, a method patent relating to a variation in a gene known as FLT3 that is used to qualify some leukemia patients for bone marrow transplant is forcing physicians and laboratories to split and geographically distribute irreplaceable bone marrow specimens. "Splitting samples not only creates an additional risk of specimen loss and delays the receipt of patient results," stated Dr. Klein, "it interferes with the ability of pathologists to provide synoptic interpretations involving multiple tests and prevents them from implementing cost saving algorithms that restrict testing to those tests that are truly necessary."

In light of the preceding, AMP asked the USPTO to place a moratorium on issuing gene patents. "By ceasing to grant gene patents, the USPTO would protect patients' access to high quality genetic testing until the issue receives full legal, legislative, and administrative consideration," said Ms. Williams.

Explore further: U.S. Supreme Court petitioned to review AMP, et al. lawsuit on gene patents

Related Stories

U.S. Supreme Court petitioned to review AMP, et al. lawsuit on gene patents

December 15, 2011
The American Civil Liberties Union and the Public Patent Foundation have petitioned the U.S. Supreme Court to hear Association for Molecular Pathology v. U.S. Patent and Trademark Office, a case that challenges the validity ...

AMP opposes exclusive licensing of NIH proteomics patent

November 22, 2011
The Association for Molecular Pathology (AMP) opposed the National Institutes of Health (NIH) proposal to exclusively license the subject matter of a cancer-related proteonomics patent application filed by the Agency. AMP's ...

Proposed NIH genetic testing registry lacks clarity, understates costs

October 28, 2011
The Association for Molecular Pathology (AMP) submitted comments to the National Institutes of Health (NIH), in which the Association voiced concerns about the proposed Genetic Testing Registry (GTR) as currently designed, ...

AMP releases statement on diagnostics in drug labels

May 16, 2011
Today, the Association for Molecular Pathology (AMP) released its new position statement on the appropriate manner to reference diagnostic tests in drug labels. The association also met with officials from the United States ...

Association for Molecular Pathology comments on proposed changes to the common rule

October 26, 2011
Yesterday, the Association for Molecular Pathology (AMP) submitted comments on the Advanced Notice of Proposed Rulemaking (ANPRM) called, Human Subjects Research Protections: Enhancing Protections for Research Subjects and ...

Recommended for you

Forgotten strands of DNA initiate the development of immune cells

September 21, 2017
Intricate human physiological features such as the immune system require exquisite formation and timing to develop properly. Genetic elements must be activated at just the right moment, across vast distances of genomic space.

Genome editing reveals role of gene important for human embryo development

September 20, 2017
Researchers have used genome editing technology to reveal the role of a key gene in human embryos in the first few days of development. This is the first time that genome editing has been used to study gene function in human ...

A piece of the puzzle: Eight autism-related mutations in one gene

September 19, 2017
Scientists have identified a hotspot for autism-related mutations in a single gene.

Scientists identify key regulator of male fertility

September 19, 2017
When it comes to male reproductive fertility, timing is everything. Now scientists are finding new details on how disruption of this timing may contribute to male infertility or congenital illness.

New assay leads to step toward gene therapy for deaf patients

September 18, 2017
Scientists at Oregon State University have taken an important step toward gene therapy for deaf patients by developing a way to better study a large protein essential for hearing and finding a truncated version of it.

Genomic recycling: Ancestral genes take on new roles

September 18, 2017
One often hears about the multitude of genes we have in common with chimps, birds or other living creatures, but such comparisons are sometimes misleading. The shared percentage usually refers only to genes that encode instructions ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.